GEN News Highlights

UCB Engages Nodality for Single Cell Network Profiling Technology

(Page
1
of
1)

UCB Pharma inked a collaboration agreement with Nodality that will apply the latter’s single cell network profiling (SCNP) technology in the development of UCB compounds, initially focused on immunological disorders. The multiyear deal also gives UCB an option to task Nodality to develop companion diagnostics for its drug compounds.

UCB claims the collaboration will provide a valuable aid to drug development by generating new insights into disease pathways and mechanisms. “This collaboration is validation of Nodality’s unique technological approach and of the value the SCNP platform technology can bring to pharmaceutical drug development, comments David Parkinson, M.D., Nodality CEO.

The firm’s SCNP technology has been developed on the back of IP licensed from Stanford University. The system effectively provides functional pathway analysis of signaling networks that regulate cellular functions such as growth, proliferation, and survival at the single cell level in potentially millions of cells. This allows the evaluation of changes in cell signaling networks that result from the administration of factors including chemokines, growth factors, small molecules, or biotherapeutics.

Because information from cells is captured independently, the approach can identify rare cells such as drug-resistant and stem cells. Nodality is exploiting its SCNP platform through partnerships with pharmaceutical and biotechnology companies, both for drug development applications and for generating companion diagnostics.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

38.9%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

22.2%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.